Imran Talat 4

What Happened
Imran Talat, Chief Executive Officer of Rani Therapeutics (RANI), received a derivative equity award on June 3, 2026 covering 3,800,000 shares. The Form 4 reports the acquisition price as $0.00 (a grant/award entry), indicating this was an equity award (described in the filing as an option) rather than an open-market purchase or sale. There was no immediate sale of shares reported.

Key Details

• Transaction date: 2026-06-03; Filing date: 2026-06-05 (filed timely).
• Transaction type/code: A (Grant/Award/Other acquisition) — derivative award covering 3,800,000 shares.
• Reported acquisition price: $0.00 (as shown on the Form 4). This reflects grant terms in the filing, not the market value.
• Vesting: Per footnote — vests 1/48th monthly over 4 years starting April 1, 2026, subject to continuous service under the company’s 2021 Equity Incentive Plan.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding sale, or immediate cashless exercise/sale reported.

Context
This is a standard equity grant to an executive that vests over time; it increases potential future ownership if vesting conditions are met. The filing shows a grant (derivative award) rather than a market purchase or sale — such awards are common in executive compensation and do not by themselves indicate immediate buying or selling in the market.